30 day rates of stroke and death of carotid stenting (myocardial infarction excluded)
| Study | Symptomatic patients (%) | Asymptomatic patients (%) |
| ARCHeR | 11.6 | 5.4 |
| CAPTURE | 12* | 5.4* |
| BEACH | 7.5 | 5 |
| CREATE | 15 | 3.4 |
| CREST lead-in | 5.7 | 3.8 |
| SPACE | 6.8 | N/A |
| EVA-3S | 9.6 | N/A |
| Current report | 2.5 | 1.4 |
↵* Includes myocardial infarction. Stroke and death were not reported separately for asymptomatic and symptomatic patients. The incidence of myocardial infarction in CAPTURE was 0.9% for all patients.
ARCHeR, Acculink for Revascularization of Carotids in High Risk Patients; BEACH, Boston Scientific EPI: A Carotid Stenting Trial for High Risk Surgical Patients; CAPTURE, Carotid Acculink/Accunet Post-Approval Trial to Uncover Unanticipated or Rare Events; CREATE, Carotid Revascularization with EV3 Technology Evolution; CREST, Carotid Revascularization Endarterectomy versus Stenting Trial; SPACE, Stent-Supported Percutaneous Angioplasty of the Carotid Artery versus Endarterectomy.